

PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more »
1. What is pulmonary arterial hypertension (PAH)*?
Pulmonary arterial hypertension (PAH)* is a disorder that affects the pulmonary arterythe large blood vessel that carries blood from the heart to the lungsand the hundreds of tiny blood vessels that branch off from it.
2. What are some typical symptoms of PAH*?†
Some of the typical symptoms of PAH* are caused by lack of oxygen and increased stress on the heart. These symptoms may not be obvious at first, but over time they may become more limiting. Without treatment, most patients will continue to experience increasing breathlessness and fatigue.3
Some symptoms of PAH* may include:
†Tracleer® (bosentan) and Ventavis® (iloprost) do not improve all of these symptoms. Individual results may vary. For more information, consult the full prescribing information or visit the Tracleer and Ventavis websites.
There are different causes for PAH*. In Inherited or Familial PAH*, the disease is passed down genetically from your parents. Most cases of PAH* occur in individuals with no known family history of the disorder.
4. What are endothelin and prostacyclin receptors?
Endothelin and prostacyclin are naturally occurring chemicals in the body.
Normal levels of endothelin help keep arteries open and elastic. Patients with PAH* have high levels of endothelinsuggesting that endothelin may play a role in PAH*.3 Endothelin receptor antagonists are designed to even out the imbalance of endothelin.
Prostacyclin keeps arteries open and suppresses excess cell growth and clotting. In PAH*, production of prostacyclin is impaired, so there is not enough to keep arteries open.3
Patients should always talk with their healthcare team first if there are any questions about their individual treatment.
*What is Tracleer?
Tracleer is a prescription medicine indicated for patients with certain types of pulmonary arterial hypertension (PAH), which is high blood pressure in the vessels of the lungs, (WHO Group I). Tracleer can improve your ability to exercise as measured by 6-minute walk test and can slow the worsening of your physical condition and symptoms.
Studies showing Tracleer is effective included mainly patients with NYHA Functional Class II-IV PAH. In these patients, PAH was caused by: unidentified or hereditary factors (60%); connective tissue disease (21%); being born with a hole in the heart between the left and right sides (18%).
In patients with WHO Functional Class II symptoms, Tracleer slowed the worsening of PAH, however, did not show meaningful improvement in walk distance. If you are a patient with WHO Functional Class II symptoms, your healthcare provider will consider whether the potential benefits of Tracleer outweigh the risk of liver damage, which may prevent future use of Tracleer as your disease progresses.
Tracleer is only:
It is not known if Tracleer is safe and works in children below 12 years of age.
What is the most important information I should know about Tracleer?
Tracleer is only available through the Tracleer Access Program (T.A.P.). Before you begin taking Tracleer, you must read and agree to all of the instructions in T.A.P. Because of potential liver damage and in an effort to make the chance of fetal exposure to Tracleer® (bosentan) as small as possible, Tracleer may be prescribed only through the Tracleer Access Program (T.A.P.), by calling 1-866-228-3546. Adverse events can also be reported directly via this number.
Liver damage:
Serious birth defects:
Who should not take Tracleer?
Do not take Tracleer if you:
What are the possible side effects of Tracleer?
Tracleer can cause serious side effects, including:
The most common side effects of Tracleer are: respiratory tract infection, headache, fainting, flushing, low blood pressure, inflamed nose passages (sinusitis), joint pain and irregular heartbeats.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Tracleer. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see full Prescribing Information and Medication Guide for Tracleer.
*What is Ventavis?
Ventavis is a prescription medicine used to treat adults with certain kinds of severe pulmonary arterial hypertension (PAH), a condition in which blood pressure is too high in the blood vessels between the heart and the lungs. Ventavis may improve your ability to exercise and your symptoms for a short time by lowering your blood pressure and opening up the blood vessels in your lungs.
The study showing Ventavis is effective included mainly patients with NYHA Functional Class III-IV PAH. In these patients, PAH was caused by unidentified or hereditary factors (65%) or connective tissue diseases (23%).
Ventavis has not been studied in children younger than 18 years old.
What is the most important information I should know about Ventavis?
Ventavis may not be right for you. Before taking Ventavis, tell your doctor about all of your medical conditions, including if you have liver or kidney problems; are pregnant, or plan to become pregnant; or are breast-feeding. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take medicines used to treat high blood pressure or heart problems or medicines that lessen blood clotting (warfarin, Coumadin, Jantoven). Ventavis and other medicines may affect each other, causing side effects.
What are the possible side effects of Ventavis?
Talk to your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Ventavis. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Please see full Prescribing Information for Ventavis.
References: 1. Adapted from Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43-S54. 2. Gibbs J. Making a Diagnosis in PAH. Eur Respir Rev. 2007;16:102,8-12. 3. McLaughlin V, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-1431. 4. TRACLEER® (bosentan) full Prescribing Information. Actelion Pharmaceuticals US, Inc., February 2011. 5. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903. 6. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-1123.